You are here

AURITEC PHARMACEUTICALS, INC.

Company Information
Address
2285 E FOOTHILL BLVD
PASADENA, CA 91107-3658
United States


http://www.auritecpharma.com/

Information

UEI: QX8KP6JKQ2L8

# of Employees: 6


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes

    Amount: $1,025,000.00

    SUMMARY The broad, long-term goal of this project is to develop a pritelivir intravaginal ring (IVR) for the treatment and pre-exposure prophylaxis of genital herpes, a common problem that affects mor ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Long-acting injectable tacrolimus for chronic immunosuppression

    Amount: $2,047,614.00

    PROJECT SUMMARY The broad, long-term goal of this Direct to Phase II SBIR is to improve immunosuppression outcomes in organ transplant recipients by developing a long-acting injectable calcineurin inh ...

    SBIRPhase II2022Department of Health and Human Services National Institutes of Health
  3. Longer-acting intravaginal formulation of buprenorphine

    Amount: $1,690,670.00

    PROJECT SUMMARY The broad, long-term goal of this research program is to empower women suffering from opioid use disorder (OUD) through the development of a long-acting intravaginal ring (IVR) formula ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  4. I-Corps: Longer-acting intravaginal formulation of buprenorphine

    Amount: $308,608.00

    PROJECT SUMMARY The broad, long-term goal of this research program is to empower women suffering from opioid use disorder (OUD) through the development of a long-acting intravaginal ring (IVR) formula ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  5. IND-enabling preclinical development of a sustained-release Pritelivir intravaginal ring for the treatment and prophylaxis of Genital Herpes in women

    Amount: $1,860,561.00

    SUMMARY (changes are underlined) The broad, long-term goal of this project is to develop a pritelivir intravaginal ring (IVR) for the treatment and pre-exposure prophylaxis of genital herpes, a common ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  6. IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy

    Amount: $1,999,996.00

    SUMMARY (changes are underlined) The broad, long-term goal of this research program is to develop an intravaginal multipurpose prevention technology (MPT) product to provide HIV pre-exposure prophylax ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  7. Preclinical development of an intravaginal ring for the sustained release of Pritelivir for the treatment and prophylaxis of Genital Herpes in women

    Amount: $224,484.00

    SUMMARY The broadlong term goal of this project is to develop a pritelivir intravaginal ringIVRfor the treatment and pre exposure prophylaxis of genital herpesa common problem that affects more thanmi ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  8. Preclinical development of an intravaginal ring for the sustained release of octreotide for the treatment of acromegaly

    Amount: $224,881.00

    PROJECT SUMMARY The broad long term goal of this research program is to develop a novel treatment for women with acromegaly a sustained release intravaginal ring IVR formulation for octreotide In ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  9. Preclinical development of a multipurpose intravaginal ring for the prevention of HIV and unintended pregnancy

    Amount: $219,324.00

    DESCRIPTION provided by applicant The broad long term goal of this research program is to develop a dual protection intravaginal product that will provide contraception and pre exposure HIV prophy ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  10. Clinical Safety and Pharmacokinetics of Sustained Release Depot Tacrolimus

    Amount: $1,299,084.00

    PROJECT SUMMARY The long term goal of this research is to reduce toxicity and graft rejection due to dosing problems with the calcineurin inhibitors by developing a sustained release subcutaneous inj ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government